World Heart Federation Cholesterol Roadmap

2013 Perel, 2015, Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease, Glob Heart, 10, 99, 10.1016/j.gheart.2015.04.003 Grainger Gasser, 2015, Reducing cardiovascular mortality through tobacco control: a World Heart Federation Roadmap, Glob Heart, 10, 123, 10.1016/j.gheart.2015.04.007 Adler, 2015, Reducing cardiovascular mortality through prevention and management of raised blood pressure: a World Heart Federation Roadmap, Glob Heart, 10, 111, 10.1016/j.gheart.2015.04.006 Palafox, 2017, The WHF Roadmap for reducing CV morbidity and mortality through prevention and control of RHD, Glob Heart, 12, 47, 10.1016/j.gheart.2016.12.001 Murphy, 2017, The Word Heart Federation Roadmap for nonvalvular atrial fibrill, 7tion, Glob Heart, 10.1016/j.gheart.2017.01.015 Mendis, 2011 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 O'Donnell, 2010, Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study, Lancet, 376, 112, 10.1016/S0140-6736(10)60834-3 Farzadfar, 2011, National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants, Lancet, 377, 578, 10.1016/S0140-6736(10)62038-7 Imperial College, Environment and Global Health Research Group. Mean Age-Standardized Cholesterol, mmol/L. Available at: http://wwwf.imperial.ac.uk/medicine/apps/ezzati/metabolic_risks/cholesterol/. Accessed January 22, 2017. 2007 Mendis, 2007, World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries, J Hypertens, 25, 1578, 10.1097/HJH.0b013e3282861fd3 Gaziano, 2008, Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I follow-up study cohort, Lancet, 371, 923, 10.1016/S0140-6736(08)60418-3 Murray, 2003, Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 361, 717, 10.1016/S0140-6736(03)12655-4 Yusuf, 2014, Cardiovascular risk and events in 17 low-, middle-, and high-income countries, N Engl J Med, 371, 818, 10.1056/NEJMoa1311890 Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4 Catapano, 2016, Atherosclerosis, 253, 281, 10.1016/j.atherosclerosis.2016.08.018 Kraus, 2002, Effects of the amount and intensity of exercise on plasma lipoproteins, N Engl J Med, 347, 1483, 10.1056/NEJMoa020194 Hooper, 2015, Reduction in saturated fat intake for cardiovascular disease, Cochrane Database Syst Rev, CD011737 Mozaffarian, 2009, Health effects of trans-fatty acids: experimental and observational evidence, Eur J Clin Nutr, 63, S5, 10.1038/sj.ejcn.1602973 Reiner, 2011, ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Mozaffarian, 2016, Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review, Circulation, 133, 187, 10.1161/CIRCULATIONAHA.115.018585 Anand, 2015, Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: a report from the workshop convened by the World Heart Federation, J Am Coll Cardiol, 66, 1590, 10.1016/j.jacc.2015.07.050 D'Agostino, 2008, General cardiovascular risk profile for use in primary care: the Framingham Heart Study, Circulation, 117, 743, 10.1161/CIRCULATIONAHA.107.699579 Perk, 2012, Eur Heart J, 33, 1635, 10.1093/eurheartj/ehs092 Ray, 2014, The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011, Eur Heart J, 35, 960, 10.1093/eurheartj/ehu107 Yusuf, 2016, Cholesterol lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 374, 2021, 10.1056/NEJMoa1600176 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 UK National Health Service. NHS Health Check: Your NHS Health Check Guide. London, UK: NHS. Available at: http://www.nhs.uk/Conditions/nhs-health-check/Pages/What-is-an-NHS-Health-Check.aspx. Accessed August 12, 2016. Dyakova, 2016, Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, CD010411 Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2935, 10.1016/j.jacc.2013.11.005 2007 Rifai, 2006, Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors, 903 Simundic, 2014, Standardization of collection requirements for fasting samples: for the Working Group on Preanalytical Phase (WG-PA) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), Clin Chim Acta, 432, 33, 10.1016/j.cca.2013.11.008 Nordestgaard, 2016, Eur Heart J, 37, 1944, 10.1093/eurheartj/ehw152 Zhao, 2015, Cardiovascular risk assessment: a global perspective, Nat Rev Cardiol, 12, 301, 10.1038/nrcardio.2015.28 Gandhi, 2012, Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age, J Infect Dis, 205, S353, 10.1093/infdis/jis202 McGorrian, 2011, Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score, Eur Heart J, 32, 581, 10.1093/eurheartj/ehq448 Hajifathalian, 2015, A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys, Lancet Diabetes Endocrinol, 3, 339, 10.1016/S2213-8587(15)00081-9 Mortensen, 2015, The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study, Eur Heart J, 36, 2446, 10.1093/eurheartj/ehv251 Sniderman, 2016, Risk of premature cardiovascular disease vs the number of premature cardiovascular events, JAMA Cardiol, 1, 492, 10.1001/jamacardio.2016.0991 Pencina, 2014, Application of new cholesterol guidelines to a population-based sample, N Engl J Med, 370, 1422, 10.1056/NEJMoa1315665 Thanassoulis, 2016, Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease, Circulation, 133, 1574, 10.1161/CIRCULATIONAHA.115.018383 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, CD004816 Collins, 2016, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, 388, 2532, 10.1016/S0140-6736(16)31357-5 2015 Boekholdt, 2014, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, J Am Coll Cardiol, 64, 485, 10.1016/j.jacc.2014.02.615 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664 Landmesser, 2016, European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk, Eur Heart J, 10.1093/eurheartj/ehw480 Lloyd-Jones, 2016, J Am Coll Cardiol, 68, 92, 10.1016/j.jacc.2016.03.519 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 Navarese, 2015, Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis, Ann Intern Med, 163, 40, 10.7326/M14-2957 Raal, 2015, Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial, Lancet, 385, 341, 10.1016/S0140-6736(14)61374-X Schwartz, 2014, Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial, Am Heart J, 168, 682, 10.1016/j.ahj.2014.07.028 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025 Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, Circulation, 124, 2458, 10.1161/CIR.0b013e318235eb4d Perk, 2012, Eur Heart J, 33, 1635, 10.1093/eurheartj/ehs092 2003 Watts, 2014, Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation, Int J Cardiol, 171, 309, 10.1016/j.ijcard.2013.11.025 Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur Heart J, 34, 3478, 10.1093/eurheartj/eht273 Benn, 2012, Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication, J Clin Endocrinol Metab, 97, 3956, 10.1210/jc.2012-1563 Mathews, 2015 Humphries, 2006, Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk, J Med Genet, 43, 943, 10.1136/jmg.2006.038356 Marks, 2000, Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis, Health Technol Assess, 4, 1, 10.3310/hta4290 Youngblom, 1993, Familial hypercholesterolemia Gidding, 2015, The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association, Circulation, 132, 2167, 10.1161/CIR.0000000000000297 Gidding, 2012, Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction, Pediatrics, 129, e1311, 10.1542/peds.2011-2903 Marks, 2002, Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia, BMJ, 324, 1303, 10.1136/bmj.324.7349.1303 Norman, 2016, Challenges in the health economics of familial hypercholesterolemia, Curr Opin Lipidol, 27, 563, 10.1097/MOL.0000000000000365 Joshi, 2014, Prevalence of hypertension and associated cardiovascular risk factors in an urban slum in Nairobi, Kenya: a population-based survey, BMC Public Health, 14, 1177, 10.1186/1471-2458-14-1177 Gaziano, 2010, Growing epidemic of coronary heart disease in low- and middle-income countries, Curr Probl Cardiol, 35, 72, 10.1016/j.cpcardiol.2009.10.002 Roth, 2011, High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries, Bull World Health Organ, 89, 92, 10.2471/BLT.10.079947 Hyre, 2007, Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults, Ann Epidemiol, 17, 548, 10.1016/j.annepidem.2007.01.032 Oguoma, 2015, Prevalence of cardiovascular disease risk factors among a Nigerian adult population: relationship with income level and accessibility to CVD risks screening, BMC Public Health, 15, 397, 10.1186/s12889-015-1709-2 Lotufo, 2016, Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), J Clin Lipidol, 10, 568, 10.1016/j.jacl.2015.12.029 Kotseva, 2016, EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries, Eur J Prev Cardiol, 23, 636, 10.1177/2047487315569401 Yusuf, 2011, Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey, Lancet, 378, 1231, 10.1016/S0140-6736(11)61215-4 De Backer, 2015, Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology, Atherosclerosis, 241, 169, 10.1016/j.atherosclerosis.2015.04.809 Civeira, 2004, Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia, Atherosclerosis, 173, 55, 10.1016/j.atherosclerosis.2003.11.010 Banerjee, 2016, Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review, Open Heart, 3, e000438, 10.1136/openhrt-2016-000438 Robbins, 2011, Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age, Prev Chronic Dis, 8, A123 Khatib, 2016, Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data, Lancet, 387, 61, 10.1016/S0140-6736(15)00469-9 Eaddy, 2012, How patient cost-sharing trends affect adherence and outcomes: a literature review, P T, 37, 45 Bowry, 2011, A systematic review of adherence to cardiovascular medications in resource-limited settings, J Gen Intern Med, 26, 1479, 10.1007/s11606-011-1825-3 Schroder, 2016, Socioeconomic inequalities in access to treatment for coronary heart disease: a systematic review, Int J Cardiol, 219, 70, 10.1016/j.ijcard.2016.05.066 Howard, 2006, Impact of health literacy on socioeconomic and racial differences in health in an elderly population, J Gen Intern Med, 21, 857, 10.1111/j.1525-1497.2006.00530.x Bohan, 2016 Yusuf, 2016, Why do people not take life-saving medications? The case of statins, Lancet, 388, 943, 10.1016/S0140-6736(16)31532-X Drain, 2014, Diagnostic point-of-care tests in resource-limited settings, Lancet Infect Dis, 14, 239, 10.1016/S1473-3099(13)70250-0 Phillips, 1988, How accurately does the Reflotron dry-chemistry system measure plasma total cholesterol levels when used a community-screening device, Med J Aust, 149, 122, 10.5694/j.1326-5377.1988.tb120533.x Pluddemann, 2012, Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update, Br J Gen Pract, 62, e224, 10.3399/bjgp12X630241 Rapi, 2009, Point-of-care testing of cholesterol and triglycerides for epidemiologic studies: evaluation of the multicare-in system, Transl Res, 153, 71, 10.1016/j.trsl.2008.11.010 Cameron, 2009, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis, Lancet, 373, 240, 10.1016/S0140-6736(08)61762-6 Olcay, 2005 Mrazek, 2002, Pharmaceutical pricing in the developing world: issues of access to medicines, Expert Rev Pharmacoecon Outcomes Res, 2, 43, 10.1586/14737167.2.1.43 2000 Patel, 2010, “This body does not want free medicines”: South African consumer perceptions of drug quality, Health Policy Plan, 25, 61, 10.1093/heapol/czp039 2015 Bobrow, 2014, Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trial, BMC Public Health, 14, 28, 10.1186/1471-2458-14-28 Perel, 2015, Adapting the World Heart Federation Roadmaps at the national level: next steps and conclusions, Glob Heart, 10, 135, 10.1016/j.gheart.2015.04.004